DelveInsight’s latest market intelligence report, “OMS-906 Sales Forecast, and Market Size Analysis – 2034,” provides a comprehensive evaluation of OMS-906 (zaltenibart), highlighting its clinical profile, regulatory trajectory, competitive positioning, and long-term revenue potential across the seven major markets (7MM) — the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
As innovation in complement-mediated and immunological disorders accelerates, OMS-906 has emerged as a high-interest investigational therapy with the potential to reshape treatment paradigms in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Glomerulonephritis (GN).
Download the Full OMS-906 Market Forecast Report (2024–2034) to gain exclusive insights into projected sales, competitive positioning, and growth opportunities across the 7MM – OMS-906 Sales Market
Strategic Market Outlook for OMS-906
According to DelveInsight’s in-depth analysis, the OMS-906 market is projected to undergo significant transformation through 2034, driven by expanding clinical adoption, improved treatment outcomes, and potential label expansion across multiple complement-mediated diseases.
The report provides a granular breakdown of OMS-906’s anticipated sales performance, uptake patterns, pricing strategies, reimbursement outlook, and competitive benchmarking. With increasing recognition of upstream complement inhibition as a therapeutic strategy, OMS-906 is positioned within a dynamic and evolving immunology landscape.
OMS-906: Drug Overview and Mechanism of Action
OMS-906, also known as zaltenibart, is a humanized IgG4 monoclonal antibody that selectively targets mannan-binding lectin-associated serine protease-3 (MASP-3). MASP-3 plays a pivotal role as the key activator of complement factor D (CFD) within the alternative complement pathway (AP).
By binding to MASP-3, OMS-906 inhibits the maturation of CFD, thereby suppressing activation of the alternative pathway at an upstream level. This mechanism enables potent control of both intravascular and extravascular hemolysis in PNH, potentially offering advantages over traditional C5 inhibitors.
Clinical data from Phase Ib studies demonstrated:
- Dose-proportional pharmacokinetics
- Rapid suppression of mature complement factor D
- Increases in hemoglobin levels
- Reduction in lactate dehydrogenase (LDH) and reticulocyte counts
- Achievement of transfusion independence in treatment-naïve and ravulizumab-suboptimal PNH patients
OMS-906 is administered via intravenous or subcutaneous routes, with a long half-life supporting monthly or less frequent dosing schedules.
Request a Complimentary Sample Report Today to explore detailed clinical data, regulatory milestones, and revenue projections for OMS-906 in PNH and Glomerulonephritis @ https://www.delveinsight.com/sample-request/oms-906-sale-forecast-and-market-analysis
Corporate and Licensing Milestones
In December 2025, Omeros Corporation announced the completion of an asset sale and licensing agreement with Novo Nordisk for zaltenibart (formerly OMS-906). Under the agreement, Novo Nordisk acquired global rights to the asset in a transaction valued at USD 240 million upfront.
This strategic acquisition underscores the commercial and clinical confidence in MASP-3 inhibition as a differentiated approach in complement-driven disorders. Novo Nordisk’s global development infrastructure and commercialization capabilities are expected to accelerate OMS-906’s regulatory pathway and international market penetration.
OMS-906 Clinical Development Status
OMS-906 is currently in Phase II clinical development for:
- Paroxysmal Nocturnal Hemoglobinuria (PNH) – NCT06298955
- Glomerulonephritis – NCT06209736
The report provides comprehensive coverage of trial designs, endpoints, study timelines, and anticipated completion dates. It also analyzes clinical differentiation relative to existing complement inhibitors and emerging late-stage pipeline assets.
Connect with Our Analysts to understand how OMS-906’s evolving clinical and commercial landscape could impact your immunology portfolio strategy @ https://www.delveinsight.com/report-store/oms-906-sale-forecast-and-market-analysis
OMS-906 Market Forecast Through 2034
DelveInsight’s forecast model evaluates:
- Current and projected market size across the 7MM
- Peak sales projections
- Uptake curves based on competitive dynamics and regulatory timing
- Label expansion potential into adjacent complement-mediated indications
The analysis suggests that OMS-906’s upstream mechanism, combined with demonstrated clinical benefits, could drive steady adoption in patients inadequately controlled on C5 inhibitors or those seeking more comprehensive complement pathway suppression.
Increased awareness of complement biology and real-world evidence supporting upstream inhibition are expected to positively influence physician confidence and payer acceptance.
OMS-906 Competitive Landscape and Market Positioning
The complement therapeutics market has seen notable growth, particularly in PNH and related renal indications. OMS-906 differentiates itself through:
- Upstream inhibition at the MASP-3 level
- Potential to address both intravascular and extravascular hemolysis
- Long-acting dosing profile
- Subcutaneous administration flexibility
The report benchmarks OMS-906 against existing therapies and emerging pipeline candidates, evaluating:
- Efficacy and safety comparisons
- Market access considerations
- Patent exclusivity timelines
- Generic entry risks
With several late-stage therapies expected to enter the market over the next decade, competitive intensity is projected to increase. However, OMS-906’s unique targeting strategy may allow it to carve out a strong niche among complement inhibitors.
Schedule a Strategic Consultation to evaluate OMS-906’s market potential, pricing outlook, and competitive intelligence in the complement therapeutics space @ OMS-906 Market Dynamics and Trends
OMS-906 Geographic Analysis: 7MM Focus
United States
The US represents the largest revenue opportunity due to high diagnosis rates, advanced biologics infrastructure, and favorable reimbursement pathways.
Europe (EU4 and the UK)
Germany, France, Italy, Spain, and the UK collectively offer significant growth potential, particularly as rare disease frameworks and early access programs support novel biologics.
Japan
Japan’s rare disease policies and increasing focus on precision immunology therapies position it as a strategic expansion market.
The report evaluates regulatory pathways, expected launch timelines, and country-specific pricing considerations across these geographies.
OMS-906 Regulatory & Commercial Milestones
DelveInsight provides a structured overview of:
- Key regulatory designations granted to OMS-906
- Anticipated approval timelines
- Commercial launch sequencing
- Licensing agreements and strategic collaborations
- M&A developments impacting market positioning
Regulatory incentives such as orphan drug designations may further enhance OMS-906’s commercial viability by offering exclusivity benefits and accelerated review opportunities.
OMS-906 SWOT Analysis and Analyst Perspective
The OMS-906 report includes a detailed SWOT analysis, assessing:
Strengths:
- First-in-class MASP-3 inhibition
- Strong mechanistic rationale
- Promising early-phase data
- Backing from a major global pharmaceutical company
Weaknesses:
- Competitive complement inhibitor landscape
- Ongoing clinical validation required
Opportunities:
- Expansion into additional complement-mediated disorders
- Increased recognition of upstream pathway inhibition
- Favorable rare disease frameworks
Threats:
- Emerging pipeline competitors
- Pricing pressure in biologics
- Regulatory uncertainties
DelveInsight’s analysts conclude that upstream complement inhibition could represent a paradigm shift, particularly in patients not optimally managed on C5 inhibitors.
OMS-906 Market Drivers and Barriers
OMS-906 Growth Drivers
- Rising awareness and diagnosis of complement-mediated diseases
- Unmet need for therapies addressing extravascular hemolysis
- Strong clinical data demonstrating biomarker improvements
- Strategic backing from Novo Nordisk
- Potential label expansions
OMS-906 Growth Barriers
- Increasing biosimilar and competitive biologic entries
- Pricing and reimbursement constraints
- Long-term safety data requirements
Stay Ahead of the Market Curve by subscribing for ongoing updates on OMS-906 approvals, label expansions, partnerships, and forecast revisions through 2034 @ https://www.delveinsight.com/sample-request/oms-906-sale-forecast-and-market-analysis
OMS-906 Market Methodology
The OMS-906 market forecast is constructed using a blend of:
- Primary research with key opinion leaders (KOLs)
- Secondary research from regulatory and industry databases
- Internal epidemiology and market modeling frameworks
- Historical analog analysis for complement inhibitors
Sources include regulatory authority publications, industry portals, trade journals, corporate filings, and clinical trial registries.
Key Questions Addressed in the OMS-906 Report
- What is OMS-906’s mechanism of action and route of administration?
- How does OMS-906 compare clinically and commercially to current standards of care?
- What is its projected market size through 2034 across the 7MM?
- What regulatory milestones and launch timelines are anticipated?
- How cost-effective is OMS-906 relative to competitors?
- Which emerging therapies pose the strongest competitive threat?
- What are the strategic implications for portfolio decision-making?
OMS-906 Future Outlook
Over the next decade, the OMS-906 market is expected to evolve significantly, supported by broader adoption, growing prescription volumes, and expansion into multiple immunological indications.
The launch of late-stage emerging therapies in PNH and Glomerulonephritis will intensify competition; however, OMS-906’s differentiated upstream inhibition approach may enable durable market positioning.
DelveInsight’s comprehensive forecast through 2034 equips stakeholders—including pharmaceutical companies, investors, healthcare strategists, and policymakers—with actionable insights to navigate the evolving immunology landscape.
As complement science advances and regulatory pathways mature, OMS-906 stands at the forefront of innovation in targeted immune modulation.
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting